BioSig Technologies' Common Stock To Resume Trading On The Nasdaq Exchange, Wednesday, October 23, 2024 After Its Appeal Was Granted An Extension Until March 7, 2025
BioSig Technologies' Common Stock To Resume Trading On The Nasdaq Exchange, Wednesday, October 23, 2024 After Its Appeal Was Granted An Extension Until March 7, 2025
BioSig Technologies, Inc. (OTCQB:BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities ("MVLS") requirement previously became non-compliant.
BioSig Technologies, Inc. (OTCQB:BSGM)（"BioSig"或"公司"），一家醫療科技公司，爲心臟內信號可視化提供前所未有的準確性和精度，今天宣佈成功上訴納斯達克委員會（NASDAQ Panel），因此公司的普通股將於2024年10月23日星期三開市時恢復在納斯達克資本市場交易所交易。公司獲得了延期至2025年3月7日的授權，這是自市值證券上市要求不符合的時點起的360天容忍期。
